Sensei Biotherapeutics: Jumps on new data from head-and-neck cancer drug study

Faeth Therapeutics,

20/05/2021 16:05

** Shares of drug developer  SNSE.O  up ~15% at $11.17,
third straight session of gains
    ** SNSE on Wednesday after market reported new data from its
early-to-mid stage trial of its lead candidate, SNS-301, in
combo with cancer drug Keytruda in head and neck cancer patients
    ** Says one patient achieved a tumor reduction of 71% that
is still ongoing after 11 months of therapy
    ** 7 patients achieved stable disease, which implies no
increase or decrease in cancer severity - SNSE  urn:newsml:reuters.com:*:nGNX6PGfJY
    ** Co said the safety profile of combination therapy was
favorable and consistent with previously reported data
    ** Data to be presented as a poster at the 2021 American
Society of Clinical Oncology (ASCO) annual meeting - SNSE
    ** Stock down 48.5% since market debut in February

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))